These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 779697)

  • 41. The treatment of bacterial infections in the newborn infant.
    Dashefsky B; Klein JO
    Clin Perinatol; 1981 Oct; 8(3):559-77. PubMed ID: 7030577
    [No Abstract]   [Full Text] [Related]  

  • 42. [Studies on human gamma-globulin of placental origin. II. Experiments on antibacterial effect].
    Hein H
    Arzneimittelforschung; 1965 Jul; 15(7):785-96. PubMed ID: 4159769
    [No Abstract]   [Full Text] [Related]  

  • 43. [Results of the treatment of corneo-conjunctival infections with Didrosulfon].
    David M; Glăvan II; Midan F
    Otorinolaringologie; 1974; 19(2):173-6. PubMed ID: 4136429
    [No Abstract]   [Full Text] [Related]  

  • 44. [Our experiences with precocious use of gentamicin in enteral infections in the newborn infant period].
    Paradiso M; Senigagliesi L; Barbanti A
    G Ital Chemioter; 1969; 16(1):283-9. PubMed ID: 4935435
    [No Abstract]   [Full Text] [Related]  

  • 45. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparative study on antibacterial effects of huangqin-tang and its metabolites produced by intestinal flora].
    Yan MZ; Zuo F; Song HY; Ye WH; Zhou ZM
    Zhongguo Zhong Yao Za Zhi; 2003 Mar; 28(3):243-6. PubMed ID: 15015311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Use of massive doses of penicillin for otogenic intracranial complications].
    Skopina EL; Rogova EG
    Vestn Otorinolaringol; 1973; 34(4):28-30. PubMed ID: 4576737
    [No Abstract]   [Full Text] [Related]  

  • 48. Antibacterial activity of lividomycin toward R factor-resistant strains of Escherichia coli.
    Yamaguchi M; Kobayashi F; Mitsuhashi S
    Antimicrob Agents Chemother; 1972 Feb; 1(2):139-42. PubMed ID: 4618453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lividomycin therapy in intestinal infections with special reference to the combined use of lividomycin and AB-PC].
    Takahashi R; Kato S
    Kansenshogaku Zasshi; 1973 Aug; 47(8):283-8. PubMed ID: 4202860
    [No Abstract]   [Full Text] [Related]  

  • 50. [Ototoxicity of aminoglucosides. A case of deafness after lividomycin].
    Kuntzmann F; Weiss JM; Berthel M; Colonna JC; Conraux C; Reinhardt W; Brogard JM; Federspil P
    Nouv Presse Med; 1979 Apr; 8(19):1604-5. PubMed ID: 258790
    [No Abstract]   [Full Text] [Related]  

  • 51. A facile synthesis of derivatives of lividosamine, a component of lividomycin B.
    Jegou E; Cleophax J; Leboul J; Gero SD
    Carbohydr Res; 1975 Dec; 45():323-6. PubMed ID: 1044289
    [No Abstract]   [Full Text] [Related]  

  • 52. Structure of LL-BM408 an aminocyclitol antibiotic.
    Kirby JP; Borders DB; Van Lear GE
    J Antibiot (Tokyo); 1977 Feb; 30(2):175-7. PubMed ID: 849918
    [No Abstract]   [Full Text] [Related]  

  • 53. [Antibiotics Aminosidin (Paromomycin). III. Some amino acid derivatives and their biological activity].
    Sawada Y; Okuno T; Taniyama H
    Yakugaku Zasshi; 1976 May; 96(5):557-564. PubMed ID: 987186
    [No Abstract]   [Full Text] [Related]  

  • 54. Synthesis of lividomycin A 5''-phosphate, an enzymatically inactivated lividomycin A.
    Yamamoto H; Kondo S; Maeda K; Umezawa H
    J Antibiot (Tokyo); 1972 Aug; 25(8):485-6. PubMed ID: 4648492
    [No Abstract]   [Full Text] [Related]  

  • 55. Deneosaminyllividomycin B.
    Yamaguchi T; Kamiya K; Mori T; Oda T
    J Antibiot (Tokyo); 1977 Apr; 30(4):332-3. PubMed ID: 585689
    [No Abstract]   [Full Text] [Related]  

  • 56. [In-vivo antibacterial activity of an aminoglucoside antibiotic: lividomycin A].
    Marmo E; Cazzola M; Brita G; Paciello C
    Arch Monaldi; 1975; 30(4):311-7. PubMed ID: 779697
    [No Abstract]   [Full Text] [Related]  

  • 57. Studies on new antibiotic lividomycins. V. In vitro and in vivo antimicrobial activity of lividomycin A.
    Kobayashi F; Nagoya T; Yoshimura Y; Kaneko K; Ogata SI
    J Antibiot (Tokyo); 1972 Feb; 25(2):128-36. PubMed ID: 4624613
    [No Abstract]   [Full Text] [Related]  

  • 58. [In-vitro antibacterial activity of an aminoglucoside antibiotic: lividomycin A].
    Marmo E; Cazzola M; Brita G; Paciello C
    Arch Monaldi; 1975; 30(4):287-310. PubMed ID: 1047630
    [No Abstract]   [Full Text] [Related]  

  • 59. In vivo antibacterial activity of diaveridine-sulfonamide combinations.
    Carroll PT; Robb CA; Tippett LO; Langston JB
    Invest Urol; 1971 Jul; 9(1):21-4. PubMed ID: 4935215
    [No Abstract]   [Full Text] [Related]  

  • 60. Antimicrobial activity of 3-substituted 5-amino-1,2,4-oxadiazoles.
    Gadebusch HH; Breuer H; Miraglia G; Basch HI; Semar R
    Antimicrob Agents Chemother (Bethesda); 1969; 9():280-3. PubMed ID: 4918994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.